Concentration of Roxithromycin in the Lesions of Acne Vulgaris

Akamatsu, Hirohiko; Horio, Takeshi

doi:10.1177/147323000102900611

Cited by 4 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other antimicrobials were essentially ineffective or weakly effective in inhibiting these cytokine productions, while at the highest drug concentration, GM-CSF and IL-6 production was inhibited by both roxithromycin and erythromycin, and by roxithromycin and clindamycin, respectively. tions of other antimicrobials used in the present study were reported previously [25,26].…”

Section: Ndfx Inhibits the Proinflammatory Cytokine Production By Kermentioning

confidence: 85%

Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes

Kuwahara

Kitazawa

Kitagaki

et al. 2005

Journal of Dermatological Science

View full text Add to dashboard Cite

Section: Ndfx Inhibits the Proinflammatory Cytokine Production By Kermentioning

confidence: 85%

Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes

Kuwahara

Kitazawa

Kitagaki

et al. 2005

Journal of Dermatological Science

View full text Add to dashboard Cite

“…It accumulates at therapeutic levels in the pilosebaceous system [90]and exhibits an interesting spectrum of effects, namely direct anti-inflammatory and anti-androgenic activities. It significantly inhibits the production of lipase and neutrophil chemotactic factor by P. acnes as well as of P. acnes -induced NF-kB activation at concentrations much lower than the MIC at which the growth curve of P. acnes is not affected [34, 91].…”

Section: New Developments and Future Trendsmentioning

confidence: 99%

Update and Future of Systemic Acne Treatment

2003

View full text Add to dashboard Cite

Systemic treatment is required in patients with moderate-to-severe acne, especially when acne scars start to occur. Antibiotics with anti-inflammatory properties, such as tetracyclines (oxytetracycline, tetracycline chloride, doxycycline, minocycline and limecycline) and macrolide antibiotics (erythromycin and azithromycin) are the agents of choice for papulopustular acne, even though the emerging resistant bacterial strains are minimizing their effect, especially regarding erythromycin. Systemic antibiotics should be administered during a period of 8–12 weeks. In severe papulopustular and in nodulocystic/conglobate acne, oral isotretinoin is the treatment of choice. Hormonal treatment represents an alternative regimen in female acne, whereas it is mandatory in resistant, severe pubertal or post-adolescent forms of the disease. Compounds with anti-androgenic properties include estrogens combined with progestins, such as ethinyl estradiol with cyproterone acetate, chlormadinone acetate, desogestrel, drospirenone, levonogestrel, norethindrone acetate, norgestimate, and other anti-androgens directly blocking the androgen receptor (flutamide) or inhibiting androgen activity at various levels, corticosteroids, spironolactone, cimetidine, and ketoconazole. After 3 months of treatment control of seborrhea and acne can be obtained. Low-dose corticosteroids (prednisone, prednisolone, or dexamethasone) are indicated in patients with adrenal hyperandrogenism or acne fulminans. New developments and future trends represent low-dose long-term isotretinoin regimens, new isotretinoin formulations (micronized isotretinoin), isotretinoin metabolites, combination treatments to reduce toxicity, insulin-sensitizing agents, 5α-reductase type 1 inhibitors, antisense oligonucleotide molecules, and, especially, new anti-inflammatory agents, such as lipoxygenase inhibitors.

show abstract

Roxithromycin downregulates production of CTACK/CCL27 and MIP-3α/CCL20 from epidermal keratinocytes

et al. 2010

View full text Add to dashboard Cite

Cutaneous T cell-attracting chemokine (CTACK)/CCL27 and macrophage inflammatory protein (MIP)-3α/CCL20 are the major inflammatory chemokines involved in skin inflammation. The present study showed that roxithromycin (RXM) suppressed the TNFα-induced production of CCL27 and CCL20 in HaCaT keratinocytes and normal human keratinocytes (NHKs) in a dose-dependent manner. The production of CCL20 induced by TNFα was suppressed by the addition of inhibitors of nuclear factor kappa B (NFκB). RXM suppressed NFκB activity induced by TNFα. RXM, by regulating CCL27 and CCL20, may contribute to the modulation of inflammation.

show abstract

Concentration of Roxithromycin in the Lesions of Acne Vulgaris

Cited by 4 publications

References 3 publications

Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes

Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes

Update and Future of Systemic Acne Treatment

Roxithromycin downregulates production of CTACK/CCL27 and MIP-3α/CCL20 from epidermal keratinocytes

Contact Info

Product

Resources

About